WCLC 2025 - Posters & ePosters-P3.12.69 Updated Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: Phase 2 TRUST-I Study

P3.12.69 Updated Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: Phase 2 TRUST-I Study

Asset Subtitle

Wei Li

Meta Tag

Speaker Wei Li

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy